Innovent Biologics, Inc.

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.